Skip to Content
MilliporeSigma
  • MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.

Nature cancer (2022-04-29)
Hamed Alborzinia, Andrés F Flórez, Sina Kreth, Lena M Brückner, Umut Yildiz, Moritz Gartlgruber, Dorett I Odoni, Gernot Poschet, Karolina Garbowicz, Chunxuan Shao, Corinna Klein, Jasmin Meier, Petra Zeisberger, Michal Nadler-Holly, Matthias Ziehm, Franziska Paul, Jürgen Burhenne, Emma Bell, Marjan Shaikhkarami, Roberto Würth, Sabine A Stainczyk, Elisa M Wecht, Jochen Kreth, Michael Büttner, Naveed Ishaque, Matthias Schlesner, Barbara Nicke, Carlo Stresemann, María Llamazares-Prada, Jan H Reiling, Matthias Fischer, Ido Amit, Matthias Selbach, Carl Herrmann, Stefan Wölfl, Kai-Oliver Henrich, Thomas Höfer, Andreas Trumpp, Frank Westermann
ABSTRACT

Aberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces massive lipid peroxidation on depletion of cysteine, the rate-limiting amino acid for glutathione (GSH) biosynthesis, and sensitizes cells to ferroptosis, an oxidative, non-apoptotic and iron-dependent type of cell death. The high cysteine demand of MYCN-amplified childhood neuroblastoma is met by uptake and transsulfuration. When uptake is limited, cysteine usage for protein synthesis is maintained at the expense of GSH triggering ferroptosis and potentially contributing to spontaneous tumor regression in low-risk neuroblastomas. Pharmacological inhibition of both cystine uptake and transsulfuration combined with GPX4 inactivation resulted in tumor remission in an orthotopic MYCN-amplified neuroblastoma model. These findings provide a proof of concept of combining multiple ferroptosis targets as a promising therapeutic strategy for aggressive MYCN-amplified tumors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Necrostatin-1, ≥98% (HPLC)
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
$55.70
25 g
Estimated to ship on March 24, 2025
$226.00
Sigma-Aldrich
10058-F4, ≥98% (HPLC), solid
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
$55.70
25 g
Estimated to ship on March 24, 2025
$226.00
Sigma-Aldrich
Glutaminase Inhibitor, Compound 968, Glutaminase Inhibitor, Compd 968, is a cell-permeable, reversible inhibitor of mitochondrial glutaminase. Represses growth & invasive activity in glutaminase upregulated fibroblasts and tumor cells.
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
$55.70
25 g
Estimated to ship on March 24, 2025
$226.00
Sigma-Aldrich
BPTES, ≥95% (HPLC)
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
$55.70
25 g
Estimated to ship on March 24, 2025
$226.00
Sigma-Aldrich
Ferrostatin-1, ≥95% (HPLC)
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
$55.70
25 g
Estimated to ship on March 24, 2025
$226.00